AgingResearch.NewsJoin free
Journal of Diabetes Investigation

Frailty and low body mass index as key determinants of sodium-glucose cotransporter 2 inhibitor-specific adverse event-related discontinuation in adults aged ≥75 years: A multicenter real-world retrospective cohort study

By Taisuke Uchida, Hiroaki Ueno, Ayaka Konagata, Show 10 more authorsKazuya Shimoda
Figure 1. Cumulative incidence of SGLT2 inhibitor‐specific AE‐related discontinuation up to day 180 after SGLT2 inhibitor initiation.
Open the figure at full size
Figure 1. Cumulative incidence of SGLT2 inhibitor‐specific AE‐related discontinuation up to day 180 after SGLT2 inhibitor initiation.Cumulative incidence of SGLT2 inhibitor‐specific AE‐related discontinuation up to day 180 after SGLT2 inhibitor initiation.Uchida et al.
Cohort study of 616 peopleInterventions

180 days, multicentre, declared ties to: Ethics Board of the University of Miyazaki and Declaration of Helsinki

Paper

The paper

Taisuke Uchida, Hiroaki Ueno, Ayaka Konagata, Show 10 more authorsKazuya Shimoda

University of Miyazaki

Journal of Diabetes Investigation, 21 Aug 2026

doi.org/10.1111/jdi.70424PubMed 42626943

More on SGLT2 inhibitors